Clinical Cancer Research
Home » Resources » Clinical Cancer Research

NILE Study: Large prospective head-to-head trial finds Guardant360 is as effective as tissue testing in detecting NSCLC biomarkers

NILE Study: Large prospective head-to-head trial finds Guardant360 is as effective as tissue testing in detecting NSCLC biomarkers

Key Findings

  • Concordance between Guardant360 and tissue testing was greater than 90% for the four biomarkers with FDA-approved therapies
  • Guideline-recommended biomarker testing was completed for 95% of patients with Guardant360 vs 31% with standard-of-care tissue testing
  • Turnaround time was ~1 week faster with Guardant360 vs. SOC tissue testing

Key Findings

  • Concordance between Guardant360 and tissue testing was greater than 90% for the four biomarkers with FDA-approved therapies
  • Guideline-recommended biomarker testing was completed for 95% of patients with Guardant360 vs 31% with standard-of-care tissue testing
  • Turnaround time was ~1 week faster with Guardant360 vs. SOC tissue testing

“In a landscape where a large fraction of our patients never get their tumor genotyped because of insufficient tissue or sequential tissue testing, it would make sense to adopt a strategy where blood is used first to detect alterations.”

Dr. Vassiliki A. Papadimitrakopoulou
Department of Thoracic Head and Neck Medical Oncology
MD Anderson Cancer Center

“In a landscape where a large fraction of our patients never get their tumor genotyped because of insufficient tissue or sequential tissue testing, it would make sense to adopt a strategy where blood is used first to detect alterations.”

Dr. Vassiliki A. Papadimitrakopoulou
Department of Thoracic Head and Neck Medical Oncology
MD Anderson Cancer Center

Study Overview

A head-to-head, prospective, multicenter trial compared Guardant360 vs standard-of-care tissue testing for biomarker detection in 282 newly diagnosed patients with advanced NSCLC

Study Overview

A head-to-head, prospective, multicenter trial compared Guardant360 vs standard-of-care tissue testing for biomarker detection in 282 newly diagnosed patients with advanced NSCLC

Points for your practice

Points for your practice

Guardant360 performed similarly to tissue in the detection of guideline-recommended biomarkers

concordanse

Guardant360 performed similarly to tissue in the detection of guideline-recommended biomarkers

concordanse

Guardant360 enabled more complete biomarker assessment than tissue testing

Guardant360 enabled more complete biomarker assessment than tissue testing

Faster test results and less time waiting to make treatment decisions

Guardant360 provides test results in 9 days vs 15 for tissue

asset-2-10-x@3x

Faster test results and less time waiting to make treatment decisions

Guardant360 provides test results in 9 days vs 15 for tissue

asset-2-10-x@3x

Guardant360-first testing finds more patients than tissue-first testing

Guardant360-first testing finds more patients than tissue-first testing

NILE Study Review

Dr. Vassiliki A. Papadimitrakopoulou,
MD Anderson Cancer Center

Open chat
Message us